58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

Frederik Marmé, Claus Hanusch, Jenny Furlanetto, Patrick G. Morris, T. Link, Carsten Denkert, Peter A. Fasching, Christian Jackisch, Silvia Antolín, Christine Solbach, Philippe Aftimos, Jens Huober, M. Untch, Marija Balić, Mattea Reinisch, Jens‐Uwe Blohmer, Ana Sofia Gonçalves, Julia Rey, T. Büchele, Sibylle Loibl